The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 23, 2019
Filed:
Feb. 24, 2016
Applicant:
Alios Biopharma, Inc., South San Francisco, CA (US);
Inventors:
Guangyi Wang, Carlsbad, CA (US);
Leonid Beigelman, San Mateo, CA (US);
Anh Truong, Burlingame, CA (US);
Karin Ann Stein, Mountain View, CA (US);
Assignee:
Alios BioPharma, Inc., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4355 (2006.01); C07D 491/048 (2006.01); C07D 401/04 (2006.01); A61K 31/536 (2006.01); C07D 221/04 (2006.01); A61K 31/437 (2006.01); C07D 491/20 (2006.01); C07D 471/04 (2006.01); C07D 213/40 (2006.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01); A61K 31/444 (2006.01); A61K 31/538 (2006.01); C07D 519/00 (2006.01); A61K 31/4545 (2006.01); C07D 413/04 (2006.01); A61K 31/436 (2006.01); A61K 31/435 (2006.01); A61K 31/4375 (2006.01); A61K 31/5355 (2006.01); A61K 31/44 (2006.01);
U.S. Cl.
CPC ...
C07D 491/048 (2013.01); A61K 31/435 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4355 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/536 (2013.01); A61K 31/538 (2013.01); A61K 31/5355 (2013.01); A61K 45/06 (2013.01); C07D 213/40 (2013.01); C07D 221/04 (2013.01); C07D 401/04 (2013.01); C07D 413/04 (2013.01); C07D 471/04 (2013.01); C07D 491/20 (2013.01); C07D 519/00 (2013.01);
Abstract
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).